摘要
目的探究沙库巴曲缬沙坦钠联合美托洛尔对慢性心力衰竭(CHF)患者心功能及心肌损伤标志物的影响.方法选择本院2020年3月-2021年12月收治的75例CHF患者,按照随机数字表法分为对照组(n=37)和观察组(n=38).对照组口服美托洛尔,观察组在对照组基础上加用沙库巴曲缬沙坦钠治疗,均持续治疗3个月.比较两组临床疗效、心功能、心肌损伤标志物水平及不良反应.结果观察组的治疗总有效率97.37%较对照组的78.38%高,差异有统计学意义(P<0.05).两组治疗前心功能、心肌损伤标志物对比,组间差异无统计学意义(P>0.05);治疗后,观察组左心室舒张末期内径短于对照组,左心室射血分数、左室短轴缩短率均高于对照组,血管紧张素Ⅱ、血清肌钙蛋白T、N末端脑钠肽前体水平均低于对照组,组间差异有统计学意义(P<0.05).两组不良反应发生率对比,差异无统计学意义(P>0.05).结论沙库巴曲缬沙坦钠联合美托洛尔治疗CHF的效果确切,能够减轻心肌细胞损伤,改善患者心功能,且安全性高.
Objective To investigate the effects of sacubitril-valsartan sodium combined with metoprolol on cardiac function and myocardial injury markers in patients with chronic heart failure(CHF).Methods A total of 75 CHF patients admitted to our hospital from March 2020 to December 2021 were selected and divided into the control group(n=37)and the observation group(n=38)according to the random number table method.The control group was given metoprolol orally,and the observation group was additionally given sacubitril-valsartan sodium on the basis of the control group for 3 months.The clinical efficacy,cardiac function,myocardial injury marker levels and adverse reactions were compared between the two groups.Results The total effective rate of treatment was 97.37%higher in the observation group compared with 78.38%in the control group,and the difference was statistically significant(P<0.05).Before treatment,there were no significant differences in cardiac function and myocardial injury markers between the two groups(P>0.05);after treatment,the left ventricular end-diastolic diameter of the observation group was shorter than that of the control group,the left ventricular ejection fraction and left ventricular short-axis shortening rate were higher than those of the control group,and the levels of angiotensinⅡ,serum troponin T,and N-terminal brain natriuretic peptide precursor were lower than those in the control group,and the differences between the groups were statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Sacubitril-Valsartan sodium combined with metoprolol has a definite effect in the treatment of CHF,can reduce myocardial cell damage,improve patients'cardiac function,and has high safety.
作者
姜桂林
王发
JIANG Guilin;WANG Fa(Department of Cardiovascular Medicine,People's Hospital of Lanling County,Linyi Shandong,277700,China;Department of Thoracic Surgery,People's Hospital of Lanling County,Linyi Shandong,277700,China)
出处
《反射疗法与康复医学》
2022年第15期159-162,共4页
Reflexology And Rehabilitation Medicine
关键词
慢性心力衰竭
沙库巴曲缬沙坦钠
美托洛尔
心功能
心肌损伤标志物
Chronic heart failure
Sacubitril-Valsartan sodium
Metoprolol
Cardiac function
Markers of myocardial injury
作者简介
姜桂林(1987-),女,山东临沂人,本科,主治医师,研究方向:心内科临床疾病的诊治。
